AGMB

NASDAQ Healthcare

AgomAb Therapeutics NV - ADRs representing one common share.

Biotechnology

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

�� 市场数据

价格	$11.33
成交量	295,548
市值	557.66M
RSI（14日）	52.8
52周最高	$17.45
52周最低	$9.00
Forward P/E	-6.07

在Yahoo Finance查看 →

🎯 投资策略评分

AGMB 在各投资策略中的评分。分数越高，越符合该策略目标。

💰 Dividend Daddy 30/100

高股息率 + 低波动性

🚀 Moon Shot 16/100

高增长潜力（高贝塔 + 超卖）

🔪 Falling Knife 78/100

逆向投资（超卖 + 低于移动均线）

🎈 Over-Hyped 13/100

超买股票（潜在做空标的）

🐋 Institutional Whale 15/100

大盘、机构级别股票

🔍 策略解读

最佳匹配： 🔪 Falling Knife (78/100) — 此策略逆向投资（超卖 + 低于移动均线）.

评分最低的策略： 🎈 Over-Hyped (13/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。了解如何解读这些评分 →

📚 了解更多

本页指标

教育文章

网站资源

在文本中查找 AGMB in your text

粘贴任何文章、记录或帖子 — 工具将提取 AGMB 以及每一个其他隐藏的股票代码。

试试股票代码提取器 →

免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.